From GlobeNewswire: 2025-02-26 16:05:00

Relay Therapeutics plans to initiate the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in mid-2025 for PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer. Interim data showed a 11.4-month median PFS in 2L patients. Other breast cancer regimens are advancing, with approximately $780 million in cash available for funding.

The Phase 3 trial is a randomized study evaluating RLY-2608 + fulvestrant in PI3Kα-mutated patients who have received CDK4/6 inhibitors. Target enrollment is 540 patients, with primary endpoint of PFS. A dose of 400mg twice daily will be used, with positive food effect observed. Corporate highlights include advancing triplet regimens and entering a licensing agreement for lirafugratinib.

Financially, Relay Therapeutics had $781.3 million in cash, cash equivalents, and investments at the end of Q4 2024. Revenue for 2024 was $10 million, with R&D expenses totaling $319.1 million. Net loss was $76 million for Q4 2024. The company expects its current cash position to fund operations into the second half of 2027.



Read more at GlobeNewswire:: Relay Therapeutics Reports Fourth Quarter and Full Year